Marco Oderda

Double live surgery day at @UroMolinette! ✌️😷 ​2 simultaneous procedures performed: ✅ Kidney surgery connecting with @IrcadFrance ✅ Andrological live surgery ​Pushing the boundaries of urology. 🚀 @paolo_gontero @dottceruti @oderdam @giorgiocalleris @FedericoLavagno @medannot

Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > bit.ly/4kwv1sZ @oderdam

Histopathologic features and transcriptomic signatures do not solve the issue of magnetic resonance imaging-invisible #ProstateCancers: a matched-pair analysis. #ProstateCancer invisibility on mpMRI ≠ indolence! A matched-pair study found no histopathologic or transcriptomic differences explaining MRI-invisible tumors—some still show aggressive features. #ReadNow > bit.ly/4kwv1sZ @oderdam

oaepublish.com/webinars/mis.3… Interested in imaging of #radiorecurrent #prostatecancer? Watch this webinar!

#TOP24 TURIN ONCOLOGY PROSTATE CANCER MASTERCLASS. FOR WHO IS INTERESTED IN ADVANCING KNOWLEDGE AND SKILLS IN THE DIAGNOSIS AND TREATMENT OF PROSTATE CANCER. 🗓️ 13/12 📍Turin, IT 📲 lnkd.in/gzBucbck @paolo_gontero @UroMolinette @oderdam @GMarra_MD @peppinoiorio

Happy to speak about #laparoscopic #inguinal #lymphadenectomy!

Grande partecipazione del pubblico ieri a Bari per NOW or NEVER – Il ruolo dell’#urologo nel trattamento multimodale del #CarcinomaProstatico, tra #Chirurgia e nuove terapie #Ormonali. Responsabili Scientifici Proff. A. Briganti @Albert0Briganti e N. Suardi @urosuardi. Docenti: M. Oderda, G. Procopio, M. Scarcia, G. Simone. @oderdam @g_procopio_

🧬 Exciting new study shows how Prolaris genomic testing can help men with intermediate-risk #ProstateCancer make better treatment decisions! 📊 Patients recommended for Active Surveillance (AS) by Prolaris were 2x more likely to choose AS and 1.5x more likely to stay on it for 3 years. 🕒 #PrecisionMedicine #CancerResearch #MensHealth #Prolaris #Urology

Clincal and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer by Philip Sutera et al Full article: europeanurology.com/article/S0302-… #MedTwitter #UroSoMe #PCa #ProstateCancer

12-13-14/06 2024 ⤵️ 🔎 Laparoscopy training course in Urology 📍 @unito @cittasalute_to ✅ Training simulation & live surgeries. We are ready 🙌 @paolo_gontero Lorenzo Repetto @PaoloDeste37946 @oderdam @Mat_Sibona Marco Allasia @FedericoLavagno CMerzagora MCatalano @SIU_Italia

Molinette Urology Equipe at @ab_medica for #SP #Davinci: @paolo_gontero @frasor86 @oderdam @p_deste

A great honor today for our family at @UroMolinette to have Prof. David Penson @urogeek with us in Turin! 🇮🇹🇺🇸 @paolo_gontero @umbertoricardi Prof.Albera Prof.ssa Cassoni @GMarra_MD @oderdam @frasor86 @MCalandri @cittasalute_to @unito @AmerUrological @VUMChealth

@paolo_gontero @AMarquis_MD @UroMolinette Well deserved!

Proud that my young former trainee ⁦@AMarquis_MD⁩ ⁦@UroMolinette⁩ the prize for best video surgery for radical cystectomy and neobladder technique in kidney transplant recipient @ the American Congress of Urology!

Secondary analysis of TITAN trial shows that half of patients with mHSPC treated with apalutamide who experienced radiographic progression developed it without corresponding PSA progression. Great team @jikei_urology @gehi87 @Keiichiro__Mori @DrShariat sciencedirect.com/science/articl…

Day one with Prof. Jean De La Rosette has gone ✅ Such inspiring talks on BPH minimally invasive treatments 🤩👌 This is our team at @UroMolinette lead by Prof. @paolo_gontero @p_deste @frasor86 @GMarra_MD @Mat_Sibona @ marcoOderda @SIU_urology @cittasalute_to @unito

Read our article @EurUrolOpen on inguinal lymphadenctomy for PeCa 😎 👉🏼 OILND vs VEILND ❌ comparable surgical outcomes ✅ VEILND quicker drain removal and less complications 👉🏼VEILND represents a safe technique authors.elsevier.com/sd/article/S26… @paolo_gontero @docctoore @oderdam

🆕 Transperineal or Transrectal MRI–targeted Biopsy for #ProstateCancer Detection 🎯 15 🇪🇺 centers - PSM 1301 matched pairs - @KoelisBx 💡ISUP2(3): 51% vs 45%; OR 1.37 (29% vs 23%; OR 1.38) @JulesBordet @sb_uro @ESRUrology @Uroweb sciencedirect.com/science/articl…

🤝🩺 The Société Internationale d’Urologie (SIU) is pleased to support the Università di Torino in helping to disseminate its 3-minute survey to shed light on the current landscape of genetic testing and the use of PARP-inhibitors in different institutions. The answers will be acquired anonymously; the data will not be accessible to third parties and will be used only for scientific purposes. 🥼🧪 The subject of how and when to use genetic tests and PARP-inhibitors in prostate cancer has become one of the hot topics in urology. Not all the institutions and countries are prepared for the widespread use of genetic testing (somatic and/or germline) and not all have access to PARP-inhibitors in their routine clinical practice. 🔎 The insights gathered from this survey will play a crucial role in identifying gaps in current practices to help improve patient care and outcomes in prostate cancer management. Answer the survey today! bit.ly/4c7ZKIC *By answering the questions, you consent to the use of the data for scientific purposes. Thank you for participating! #UroSoMe @unito @paolo_gontero @oderdam @StavrosGravas

Robot-assisted PSMA-radioguided surgery to assess surgical margins and nodal metastases in #ProstateCancer patients: Report on three cases using an intraoperative PET-CT specimen imager. #BeyondTheAbstract with @oderdam @cittasalute_to > bit.ly/3IzYnF2 @urogoldjournal